Achromatopsia clinical trials at UC Health

• Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia

  Sorry, not currently recruiting here

  This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

  at UCSF

• Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia

  Sorry, not currently recruiting here

  This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

  at UCSF

Last updated: July 7, 2020